Related Experiment Videos
Corticotropin-releasing factor decreases vasogenic brain edema
J Tjuvajev1, H Uehara, R Desai
1Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York 10021, USA.
Cancer Research
|March 15, 1996
Summary
Human corticotropin-releasing factor (hCRF) effectively reduces brain edema and improves survival in rats, offering a potential alternative to dexamethasone with fewer side effects.
Area of Science:
- Neuroscience
- Pharmacology
- Oncology
Background:
- Vasogenic peritumoral brain edema is a significant challenge in neuro-oncology.
- Corticosteroids like dexamethasone are standard treatment but have notable side effects.
Purpose of the Study:
- To compare the anti-edematous effects of human corticotropin-releasing factor (hCRF) and dexamethasone.
- To investigate the mechanism of action and survival benefits of hCRF in brain tumor edema.
Main Methods:
- Experimental model of vasogenic peritumoral brain edema using RG2 gliomas in rats.
- Contrast-enhanced T1-weighted and proton-density MRI to assess blood-brain barrier (BBB) permeability and water content.
- Direct wet/dry tissue measurements for confirmation.
- Survival studies with chronic treatment.
Main Results:
- Both hCRF and dexamethasone reduced BBB permeability and brain water content.
- hCRF demonstrated a significantly higher potency (120:1 molar basis) compared to dexamethasone.
- hCRF's action is independent of adrenal corticosteroids, acting directly on tumor microvasculature.
- Chronic hCRF treatment significantly prolonged survival compared to dexamethasone and saline controls.
Conclusions:
- hCRF is a potent agent for reducing vasogenic brain edema.
- hCRF offers a promising alternative to corticosteroid therapy with potential for reduced side effects.
- hCRF may improve survival outcomes in patients with brain tumors.